Common Contracts
4 similar Purchase Agreement contracts by Par Technology Corp, Amphastar Pharmaceuticals, Inc., Spectrum Pharmaceuticals Inc
Jefferies LLC Wells Fargo Securities, LLC BofA Securities, Inc. As Representatives of the several Initial Purchasers c/o Jefferies LLC c/o J.P. Morgan Securities LLC New York, New York 10179 c/o Wells Fargo Securities, LLC New York, New York 10001 c/o...Purchase Agreement • September 15th, 2023 • Amphastar Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Amphastar Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several initial purchasers named on Schedule A (the “Initial Purchasers”) $300,000,000 aggregate principal amount of its 2.00% Convertible Senior Notes due 2029 (the “Firm Securities”). In addition, the Company has granted to the Initial Purchasers an option to purchase up to an additional $45,000,000 aggregate principal amount of its 2.00% Convertible Senior Notes due 2029 (the “Option Securities”). The Firm Securities and the Option Securities are hereinafter referred to collectively as the “Securities.” Jefferies LLC, J.P. Morgan Securities LLC, Wells Fargo Securities, LLC and BofA Securities, Inc. have agreed to act as representatives of the several Initial Purchasers (in such capacity, the “Representatives”) in connection with the offering and sale of the Securities. Upon conversion, the Company will pay cash up to the aggregate principal amount of the Securities to be conver
PURCHASE AGREEMENTPurchase Agreement • February 10th, 2020 • Par Technology Corp • Calculating & accounting machines (no electronic computers) • New York
PAR TECHNOLOGY CORPORATION 4.500% Convertible Senior Notes due 2024 PURCHASE AGREEMENTPurchase Agreement • April 15th, 2019 • Par Technology Corp • Calculating & accounting machines (no electronic computers) • New York
SPECTRUM PHARMACEUTICALS, INC. 2.75% Convertible Senior Notes due 2018 PURCHASE AGREEMENTPurchase Agreement • December 23rd, 2013 • Spectrum Pharmaceuticals Inc • Pharmaceutical preparations • New York
This opinion is provided to you at the request of Spectrum Pharmaceuticals, Inc. (the “Company”), pursuant to Section [7(a)(vi)] of the Purchase Agreement, dated December [—], 2013 (the “Purchase Agreement”), between Jefferies LLC and RBC Capital Markets, LLC, as representative of the several Initial Purchasers listed in Schedule I thereto (collectively, the “Initial Purchasers”) and the Company. Capitalized terms below that are not otherwise defined shall have the meaning ascribed to them in the Purchase Agreement.
